SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. - Wikidata - awgldk - TriplyDB

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

http://www.wikidata.org/entity/Q37595372

about

Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity.EMT and MET: necessary or permissive for metastasis?Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Clusterization in head and neck squamous carcinomas based on lncRNA expression: molecular and clinical correlates.Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.The dark side of SOX2: cancer - a comprehensive overview.Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.Androgen receptor and miR-206 regulation in prostate cancer.Emerging Variants of Castration-Resistant Prostate Cancer.The EMT spectrum and therapeutic opportunities.The intersection of RB tumor suppressor function, stem cells, metabolism and inflammation.Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4.PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes.Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.Differential impact of RB status on E2F1 reprogramming in human cancer.Unravelling biology and shifting paradigms in cancer with single-cell sequencing.Molecular determinants of prostate cancer metastasis.Cancer cell reprogramming to identify the genes competent for generating liver cancer stem cells.Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Are there multiple cells of origin of Merkel cell carcinoma?Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.Putting p53 in Context.BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1.Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation.The Genomics of Prostate Cancer: emerging understanding with technologic advances.Biology and evolution of poorly differentiated neuroendocrine tumors.Current treatment strategies for advanced prostate cancer.Current perspectives on bone metastases in castrate-resistant prostate cancer.Leveraging and coping with uncertainty in the response of individual cells to therapy.Small Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver.PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.Identification of potential therapeutic targets in prostate cancer through a cross-species approach.New Opportunities and Challenges to Defeat Cancer Stem Cells.Transcribing malignancy: transcription-associated genomic instability in cancer.SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition.Evasion of targeted cancer therapy through stem-cell-like reprogramming.The ubiquitin ligase SCFFBXW7α promotes GATA3 degradation.

P2860

Q33767473-ADBF0D20-769D-41A2-8C4A-D9A9856070D8 Q33869775-A10549F6-2FE9-4244-9A76-47EFDD3A4F3A Q36398998-54D19300-F0B5-43A6-BEE2-2DE1FB6BFDBD Q37742485-C6F98D42-E1E0-4653-B540-5E202331FEA6 Q38607675-29EB76BB-EAC0-4245-87C4-747DC73F53E7 Q38722705-A1B8F7F3-3FAC-4D41-B46F-320CC6996F30 Q38733504-AD517880-385E-46E4-AD22-339C6C945E5C Q38836163-758231F7-EECC-45C0-807B-240327C5B707 Q38946793-9ACD9253-C80A-4CBA-91A3-218EC8950B78 Q39210257-E43A0C1B-38A8-4CD3-9188-524EDCCB56B3 Q39329818-D40F48B4-BC24-4BEF-9753-AB58A1E8C04E Q39414638-06C670E5-2C8B-48FF-B7EA-4BDD4D066B02 Q42071191-94A2E0C2-39BF-41F4-B7E8-84652C9F413C Q43293647-E41C60D0-3112-4C92-B665-5C27B763D754 Q43578455-D7B272AF-5B9C-4BB0-B448-5B9E66781D74 Q46068832-BDCB09D9-FB41-44D1-BD9C-36B3D5690B22 Q46650799-B2B67BBB-7982-4A89-BE07-EA44817B726C Q47103669-DFC8FB18-4AB7-4861-BDA5-DF242508481D Q47133533-52956431-9C4C-47D7-BD15-9B608D15955F Q47140347-558C224D-CC49-4172-89DB-692CBA573B59 Q47231171-52661058-15D8-4940-8FC5-3C91B5672A0D Q47359141-D2F6806B-6C0A-460C-AE9D-5045F0398CEF Q47555708-3CA7F408-16C3-4192-BF87-4E08EF4B701D Q47670505-01888A1E-025C-43DC-AC58-6165B3DDD89A Q47833426-B482DBEC-CAB9-4214-8E9A-9370E8245A45 Q48103261-72994345-22C7-4972-B221-255AB0AF3E8A Q48243350-E2B92D3D-697E-46AF-897E-4A39F53E05DD Q48317607-DEC2C498-E0E4-4697-B843-095E39F5EB9E Q48320507-9E971C31-24D0-49B9-B02C-9F88B43F8A1B Q48561494-D4D5D79A-0E4A-4889-BB01-F1AA854FAFA8 Q49285273-82703896-F135-434D-A805-AFFA14B5F766 Q49390409-3EE7E8C3-73EF-4F6A-ADFC-A17C9B09F306 Q49647301-BD28718A-4B03-43A1-B75B-14FEED9665E2 Q49922514-F556099E-F22E-4F28-AFFB-E5F856C8B396 Q50043890-DE814F5E-5A89-4679-98F1-52C09680ACD0 Q50094787-D60C409E-AC75-407F-ABF7-7C13FEC81475 Q50141281-0F59F78B-7F43-4D30-8112-DEAC95D7B1C4 Q50284819-A1A81759-4B1A-4FB7-9303-761E493BAD7F Q50286785-FFE3FBED-D91E-4E48-91D3-2E6BD145722C Q50525986-E06EEED7-3B5E-4962-9250-682EB13E3B7B

P2860

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

http://www.wikidata.org/entity/Q37595372

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

SOX2 promotes lineage plastici ...... RB1-deficient prostate cancer.

@en

SOX2 promotes lineage plastici ...... RB1-deficient prostate cancer.

@nl

type

label

SOX2 promotes lineage plastici ...... RB1-deficient prostate cancer.

@en

SOX2 promotes lineage plastici ...... RB1-deficient prostate cancer.

@nl

prefLabel

SOX2 promotes lineage plastici ...... RB1-deficient prostate cancer.

@en

SOX2 promotes lineage plastici ...... RB1-deficient prostate cancer.

@nl

P1433

Q37595372-080CEB44-99E8-47CD-8318-FE3E4DB98223

P1476

Q37595372-BD507E0E-D12D-4F9D-9A88-C78AE738767F

P2093

Q37595372-0C33513E-81B9-4E60-954D-6F323857A543

Q37595372-1FFEA150-43A8-426D-9EDC-B84745962F8A

Q37595372-3FF77EC5-4758-4B1C-80AF-2BA819F51510

Q37595372-4BF5217A-4A5E-4043-B7C5-D6454DE0AB30

Q37595372-4DFFC329-4DE4-448F-9F00-E8ED0F2DD5AE

Q37595372-50F35532-8B69-430B-8BDC-2579B7022F77

Q37595372-6145E39B-FACC-4139-BA93-E3759E9F9C8D

Q37595372-69EF48EA-4131-40E7-9B33-E9436635ACA9

Q37595372-6E9B88E2-AC3E-486D-90F9-B9932BE23238

Q37595372-79F7939B-71D3-4691-904C-23EF558F5F80

P2860

Q37595372-00D2E9A1-AC85-4506-A7C4-AEB6D47BBFCC

Q37595372-03EBD69C-F178-4628-B699-48DE1DCD421F

Q37595372-0532CA50-19F6-4747-86A8-33F6AF3AE821

Q37595372-076DAB5F-1B58-40FF-8685-D822D256233F

Q37595372-0BF8C2FD-DF26-4B6B-958D-0B8EA45F1C4F

Q37595372-144AA4F8-3CB0-4A92-AFCB-859FC5126A24

Q37595372-15E24FB7-452A-423E-8BF4-388C67551663

Q37595372-1D906623-D8CA-413B-9708-0AE09A1547D9

Q37595372-1FCD9899-32EA-4AC8-B3DB-458BFB703AA4

Q37595372-210ED859-3024-41F7-98F0-CFC1DA713958

P304

Q37595372-547C04F7-0C06-47AC-8904-98C612EBF0A7

P31

Q37595372-19D18695-ED84-4AF3-997A-C43739C18B39

P356

Q37595372-8FD14CBA-4AD3-4675-A5BF-AEDDCC5C4066

P407

Q37595372-82328505-3E10-4D44-A732-C4ECFCF65899

P433

Q37595372-4BC4BCCC-46C3-40D5-8228-7384AAF854EA

P478

Q37595372-87698B8C-4D30-42AB-8E2E-4168133C4714

P50

Q37595372-84B5A0D3-FE1D-49D2-AF69-F4AC3C3173BA

Q37595372-8ADB2DA1-7CDA-48F7-85D8-AC742D451029

Q37595372-8B7530E1-8241-421B-A151-C44A85EB81EA

Q37595372-B6BFDD0B-DC1B-4066-81E4-52B82D70C607

Q37595372-EF171017-4B5D-41DF-91AB-EE4A68D68314

P577

Q37595372-3E37F36B-4A27-4E21-909E-A019070F80D5

P698

Q37595372-2809ABD6-AF69-4F6C-9E47-DE0EA8366911

P932

Q37595372-5D57E600-1AD3-40B6-ACFC-0D5475364B44

P356

SCIENCE.AAH4307

P1433

P1476

SOX2 promotes lineage plastici ...... RB1-deficient prostate cancer.

@en

P2093

Charles L Sawyers

http://www.w3.org/2001/XMLSchema#string

Chi-Chao Chen

http://www.w3.org/2001/XMLSchema#string

Chun-Hao Huang

http://www.w3.org/2001/XMLSchema#string

David W Goodrich

http://www.w3.org/2001/XMLSchema#string

Davide Prandi

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hoover

http://www.w3.org/2001/XMLSchema#string

Francesca Demichelis

http://www.w3.org/2001/XMLSchema#string

Himisha Beltran

http://www.w3.org/2001/XMLSchema#string

John Wongvipat

http://www.w3.org/2001/XMLSchema#string

Leigh Ellis

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Integrative clinical genomics of advanced prostate cancer.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Overcoming mutation-based resistance to antiandrogens with rational drug design

Molecular determinants of resistance to antiandrogen therapy

P304

84-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.AAH4307

http://www.w3.org/2001/XMLSchema#string

P407

P433

6320

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P50

Elisa de Stanchina

Elizabeth J Adams

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28059768

http://www.w3.org/2001/XMLSchema#string

P932

5247742

http://www.w3.org/2001/XMLSchema#string